Aurobindo Pharma Limited
Aurobindo Pharma Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹9,150 cr of revenue in its latest quarter (Q1 FY27) and kept 11.3% of sales as profit. It is the 8th largest of 9 Pharmaceuticals companies we track, by market value.
Healthier than 61% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 33–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 57
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in AUROPHARMA?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 0%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹9,150 cr |
| Other Income | ₹264 cr |
| Total Income | ₹9,415 cr |
| Cost of Materials | ₹2,894 cr |
| Purchases of Stock-in-Trade | ₹932 cr |
| Inventory Change (±) | ₹-199 cr |
| Employee Benefit Expense | ₹1,480 cr |
| Finance Costs | ₹102 cr |
| Depreciation & Amortisation | ₹487 cr |
| Other Expenses | ₹2,162 cr |
| Total Expenses | ₹7,858 cr |
| Exceptional Items | ₹-40 cr |
| Profit before Tax | ₹1,517 cr |
| Tax Expense | ₹483 cr |
| Share of JV / Associates | ₹-2 cr |
| Net Profit | ₹1,032 cr |
| Net margin on total income | 11.0% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 8,646 cr | 8,853 cr | 9,150 cr |
| Total income | 8,834 cr | 8,970 cr | 9,415 cr |
| Expenses | 7,430 cr | 7,677 cr | 7,858 cr |
| Profit before tax | 1,338 cr | 1,293 cr | 1,517 cr |
| Tax | 429 cr | 370 cr | 483 cr |
| Net profit (owners' share) | 910 cr | 921 cr | 1,033 cr |
| Net margin (owners' share, on revenue) | 10.5% | 10.4% | 11.3% |
| EPS (₹) | 15.67 | 15.86 | 17.86 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limitedthis company | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Buyback | Buy Back of Shares | 17 Apr 2026 |
| Dividend | ₹4 / share | 8 Aug 2025 |
| Buyback | Buy Back of Shares | 30 Jul 2024 |
| Dividend | ₹1.5 / share | 20 Feb 2024 |
| Dividend | ₹3 / share | 20 Nov 2023 |
| Dividend | ₹3 / share | 17 Feb 2023 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.